{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.166","value":"230"}]}],"title":"1st Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.181","value":"305"}]}],"title":"2nd Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.183","value":"353"}]}],"title":"3rd Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.174","value":"378"}]}],"title":"4th Dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Cmax is the maximum observed plasma rituximab concentration. Cmax was assessed at each visit following 1st, 2nd, 3rd, and 4th IV dose of rituximab 375 mg/m\\^2 on Days 1, 8, 15, and 22. Cmax was calculated in micrograms per millilitre (mcg/mL).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received rituximab as an intravenous (IV) infusion of 375 milligrams per meter squared (mg/m\\^2) once a week on Days 1, 8, 15 and 22 during the Remission Induction Phase (Day 1 (baseline) to Month 6) and were followed for a minimum of 18 months (maximum 4.5yrs) during the Follow-up Phase until the Common-closeout (CCO))","id":"OG000","title":"Rituximab (Experimental)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis population included all participants in the safety population who provided at least one evaluable PK sample.","reportingStatus":"POSTED","timeFrame":"From Day 1 to Day 180","title":"Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Rituximab","type":"SECONDARY","unitOfMeasure":"mcg/mL"}